STOCK TITAN

[Form 4/A] First Tracks Biotherapeutics, Inc. Amended Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

First Tracks Biotherapeutics director equity grants: Director John A. Orwin received stock options for 7,000 shares of Common Stock at an exercise price of $17.81 per share and 2,500 Restricted Stock Units on May 12, 2026, as compensation awards, not open‑market trades.

The 2,500 RSUs each represent one share of Common Stock for no cash cost and vest 100% on the date of the company’s 2027 annual shareholder meeting, if he continues serving the company. The 7,000 stock options vest in 12 equal monthly installments starting June 12, 2026, through full vesting, also conditioned on continued service.

Positive

  • None.

Negative

  • None.
Insider Orwin John A
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 2,500 $0.00 --
Grant/Award Stock Option (right to buy) 7,000 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 2,500 shares (Direct, null); Stock Option (right to buy) — 7,000 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Stock options granted 7,000 options Grant on May 12, 2026 to director John A. Orwin
Option exercise price $17.81 per share Exercise price for 7,000 stock options
Option expiration May 11, 2036 Expiration date of stock options
RSUs granted 2,500 RSUs Grant on May 12, 2026 to director John A. Orwin
RSU settlement ratio 1 share per RSU Each RSU converts into one Common share for no consideration
RSU vesting date 2027 annual meeting date 100% of RSUs vest at 2027 shareholder meeting, subject to service
Option vesting schedule 1/12 monthly from June 12, 2026 Monthly vesting until fully vested, subject to continued service
Options held after grant 7,000 options Total options following the reported transaction
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
stock option financial
"The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vests financial
"The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders"
exercise price financial
"conversion_or_exercise_price": "17.8100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did TRAX director John A. Orwin report on May 12, 2026?

Director John A. Orwin reported receiving equity awards, not market trades. He was granted stock options for 7,000 TRAX common shares at $17.81 per share and 2,500 Restricted Stock Units, all as compensation, contingent on future service-based vesting conditions.

How many stock options did TRAX grant to director John A. Orwin and at what price?

First Tracks Biotherapeutics granted John A. Orwin stock options for 7,000 shares of Common Stock at an exercise price of $17.81 per share. These options vest monthly over 12 months beginning June 12, 2026, assuming he continues providing service to the company.

What are the key terms of John A. Orwin’s RSU grant from TRAX?

John A. Orwin received 2,500 Restricted Stock Units, each RSU representing a right to one share of TRAX Common Stock for no cash payment. The RSUs vest 100% on the date of the company’s 2027 annual shareholder meeting, contingent on his continued service through that date.

When do John A. Orwin’s TRAX stock options and RSUs vest?

The 7,000 TRAX stock options vest in 12 equal monthly installments starting June 12, 2026 until fully vested. The 2,500 RSUs vest as to 100% of the award on the date of First Tracks Biotherapeutics’ 2027 annual meeting of shareholders, subject to continued service.

Are John A. Orwin’s TRAX Form 4/A transactions open-market buys or sells?

The reported transactions are compensation awards, not open-market trades. They are coded as “A” grants, reflecting stock options and Restricted Stock Units awarded by the company. No open-market purchases or sales were reported, and transaction prices per share were shown as zero for the awards.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Orwin John A

(Last)(First)(Middle)
10770 WATERIDGE CIRCLE, SUITE 210

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
05/14/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)05/12/2026A2,500 (2) (2)Common Stock2,500$02,500D
Stock Option (right to buy)$17.8105/12/2026A7,000 (3)05/11/2036Common Stock7,000$07,000D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Remarks:
This amended Form 4, as originally filed on May 14, 2026, is being filed to correct the amount of stock options and RSUs granted to the Reporting Person. This Form 4 amendment updates both equity awards to reflect 7,000 stock options and 2,500 RSUs originally granted to the Reporting Person on May 12, 2026.
/s/ Ajim Tamboli, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)